Investor's Business Daily
•Gilead Sciences to buy CymaBay for $32.50 per share
Summary
Nutrition label
72% Informative
CymaBay is working on a treatment for a liver disease called primary biliary cholangitis.
Gilead notes the acquisition will complement its existing portfolio of liver disease drugs.
In premarket trades on today 's stock market, CyMABay stock surged 24.5% to 31.99 . The deal values shares at $ 32.50 apiece.
VR Score
68
Informative language
68
Neutral language
64
Article tone
formal
Language
English
Language complexity
57
Offensive language
possibly offensive
Hate speech
not hateful
Attention-grabbing headline
detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
3
Source diversity
2
Affiliate links
no affiliate links